Page last updated: 2024-11-05

fluocortolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluocortolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive properties. It is used topically to treat various skin conditions, including eczema, psoriasis, and allergic dermatitis. Fluocortolone is available as a cream, ointment, lotion, and spray. The synthesis of fluocortolone involves multiple steps, including halogenation, oxidation, and esterification. The compound's effects are primarily due to its interaction with glucocorticoid receptors, leading to the modulation of gene expression. Fluocortolone is studied for its potential use in treating various inflammatory and autoimmune diseases. Its importance lies in its effectiveness in reducing inflammation and its potential as a therapeutic agent for a range of conditions.'

Fluocortolone: A glucocorticoid with anti-inflammatory activity used topically for various skin disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9053
CHEMBL ID251634
CHEBI ID135581
SCHEMBL ID4644
MeSH IDM0008594

Synonyms (50)

Synonym
fluocortolone (usan/inn)
D04218
152-97-6
6-alpha-fluoro-16-alpha-methyl-1-dehydrocorticosterone
fluocortolone [usan:inn:ban]
6-alpha-fluoro-16-alpha-methyl-delta(sup 1,4)-pregnadiene-11-beta-diol-3,20-dione
fluocortolon
einecs 205-811-5
brn 3122594
fluocortolonum [inn-latin]
6-alpha-fluoro-16-alpha-methylpregna-1,4-diene-11-beta,21-diol-3,20-dione
ultralan oral
6-alpha-fluoro-11-beta,21-dihydroxy-16-alpha-methylpregna-1,4-diene-3,20-dione
fluorcortolone
6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
fluorocortolone
pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16-methyl-, (6alpha,11beta,16alpha)-
sh 742
fluocortolona [inn-spanish]
fluocortolone
CHEBI:135581
sh-742
CHEMBL251634
(6s,8s,9s,10r,11s,13s,14s,16r,17s)-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
fluocortolona
65vxc1mh0j ,
ec 205-811-5
fluocortolonum
unii-65vxc1mh0j
BCP9000698
BCP0726000096
fluocortolone [usan]
pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-
fluocortolone [inn]
fluocortolone [who-dd]
fluocortolone [jan]
fluocortolone [mart.]
fluocortolone [mi]
2-ethyl-quinazolin-4-ol
SCHEMBL4644
6alpha-fluoro-11beta,21 -dihydroxy-16alpha-methyl-1,4-pregnadiene-3,20-dione
GAKMQHDJQHZUTJ-ULHLPKEOSA-N
DB08971
J-008966
DTXSID00861835
Q5462793
(6alpha,11beta,16alpha)-6-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
16alpha-methyl-6alpha-fluoro-delta1,4-pregnadien-11beta,21-diol-3,20-dione
EN300-19767700
(1s,2r,3as,3bs,5s,9ar,9bs,10s,11as)-5-fluoro-10-hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one

Research Excerpts

Overview

Fluocortolone is a potent corticosteroid used orally for the treatment of rheumatic diseases, asthma, and immunosuppression.

ExcerptReferenceRelevance
"Fluocortolone is a potent corticosteroid used orally for the treatment of rheumatic diseases, asthma, and immunosuppression. "( Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone.
Derendorf, H; Richter, K; Rohatagi, S; Täuber, U, 1996
)
1.96

Effects

ExcerptReferenceRelevance
"Fluocortolone has the same potency as prednisone but lacks a mineralocorticoid effect."( Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy.
Coors, EA; von den Driesch, P, 2000
)
1.25

Toxicity

ExcerptReferenceRelevance
" There were few adverse effects."( Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy.
Bierman, CW; Bronsky, E; Connell, JT; Lieberman, PL; Meltzer, EO; Nathan, R; Orgel, HA; Pearlman, DS; Pence, HL; Slavin, RG, 1991
)
0.28

Pharmacokinetics

The effect of fluocortolone on cortisol suppression was characterized using a 'direct suppression pharmacodynamic model'

ExcerptReferenceRelevance
" Pharmacokinetic parameters of fluocortolone (half lives of absorption-t1/2a and elimination t1/2e, volume of distribution V and oral clearance (CL/f) were independent of the duration of treatment and dose."( Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.
Bickel, U; Matthes, H; Posern, U; Tüber, U; Voigt, K, 1988
)
2
"The effect of fluocortolone on cortisol suppression was characterized using a 'direct suppression pharmacodynamic model'."( Pharmacodynamic modeling of cortisol suppression from fluocortolone.
Jusko, WJ; Lew, KH, 1993
)
0.9
" Cortisol suppression was chosen as the pharmacodynamic parameter."( Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone.
Derendorf, H; Richter, K; Rohatagi, S; Täuber, U, 1996
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"The following is a case presentation of congenital syphilitic keratitis in a boy 6 years of age who was successfully treated with an immunosuppressive drug combination therapy."( Syphilitic interstitial keratitis: treatment with immunosuppressive drug combination therapy.
Gonzales, S; Manzotti, F; Orsoni, JG; Zavota, L, 2004
)
0.32
" In the present case report, a pediatric patient affected by syphilitic interstitial keratitis was treated successfully with an immunosuppressive drug combination therapy."( Syphilitic interstitial keratitis: treatment with immunosuppressive drug combination therapy.
Gonzales, S; Manzotti, F; Orsoni, JG; Zavota, L, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Despite the extremely low rate of absorption the slow ester hydrolysis of FCB in human skin results in a persistent, high level of active ingredient in the skin."( [Metabolism of fluocortin butylester in the skin of guinea pigs and man (author's transl)].
Herz-Hübner, U; Täuber, U, 1977
)
0.26
" The absolute bioavailability of both corticosteroids was higher than 80% and independent of both dose levels investigated."( The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration.
Haack, D; Kloss, G; Nieuweboer, B; Täuber, U; Vecsei, P; Wendt, H, 1984
)
0.57
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" In subsequent months, one third of the patients was maintained at the dosage of 3 mg/day, one third at a lower dosage of 2 mg/day, and the remaining one third of the patients at a larger dosage of 4 to 8 mg/day."( Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy.
Bierman, CW; Bronsky, E; Connell, JT; Lieberman, PL; Meltzer, EO; Nathan, R; Orgel, HA; Pearlman, DS; Pence, HL; Slavin, RG, 1991
)
0.28
" This suppression did not unequivocally correlate with the dosage or duration of treatment, but there was a tendency towards it at higher dose levels (15-30 mg)."( [Corticotropin-releasing hormone (CRH) test for monitoring glucocorticoid therapy].
Degner, FL; Juli, E; Ridderskamp, P; Schlaghecke, R, 1990
)
0.28
" This was a 4-week study with a 1-week observation (baseline) period and a 3-week period during which the response to three dosage regimens (2 mg per day, 4 mg per day, and 8 mg per day) of FCB and placebo were compared to baseline observations of rhinitis."( Efficacy and tolerance of fluocortin butyl administered twice daily in adult patients with perennial rhinitis.
Hartley, TF; Lieberman, PL; Meltzer, EO; Noyes, JN; Pearlman, DS; Tinkelman, DG, 1985
)
0.27
" Three separate dosage regimens were employed."( Multi-center, double-blind, placebo-controlled trial of fluocortin butyl in perennial rhinitis.
Arbesman, C; Bernstein, IL; Bierman, CW; Bocles, JS; Katz, R; Lieberman, PL; Mattucci, K; Meltzer, EO; Middleton, E; Noyes, J; Pearlman, DS; Pence, HL; Slavin, RG; Spector, SL, 1983
)
0.27
" We report a nine-year-old girl with widespread lichen planus, involving the nails, with no mucosal involvement and regressing after treatment with a starting dosage of 20 mg/day systemic flucortolon (Ultralan) therapy."( Childhood lichen planus with nail involvement: a case.
Ilter, N; Onder, M; Oztaş, MO; Oztaş, P,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
21-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID91225Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay; Potent1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID90219Potency relative to fluocinolone 16,17-acetonide(Experimental vasoconstictor activity)in human; NA= Not active1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (247)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990179 (72.47)18.7374
1990's37 (14.98)18.2507
2000's20 (8.10)29.6817
2010's11 (4.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.47 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials87 (32.71%)5.53%
Reviews6 (2.26%)6.00%
Case Studies71 (26.69%)4.05%
Observational0 (0.00%)0.25%
Other102 (38.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Single Exposure Bioequivalence Study to Evaluate the Vasoconstriction Activity of Topically Applied Cloderm® (Clocortolone Pivalate) 0.1% Cream and Clocortolone Pivalate 0.1% Cream (Taro Pharmaceuticals) in Healthy Male and Female Volunteers With Normal S [NCT04358770]Phase 1124 participants (Actual)Interventional2018-03-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]